Anti-HBc Total (IgG/IgM) Enzyme Immunoassay (EIA)

<<Return to Laboratory

Requisition Forms

Reference Details

Description:

Detection of total antibody (IgG and IgM) to the Hepatitis B virus core antigen marker by enzyme immunoassay (EIA).

Test Category:
Serology
Pathogen:
Hepatitis B virus (HBV)
Illnesses and Diseases:
  • Hepatitis B
Specimen:

Serum or plasma sample. Minimum volume required for serum or plasma – 0.5 mL.

Collection Method:

Collect blood in serum separator tubes (SST) or EDTA tubes.

Specimen Processing, Storage and Shipping:

Store samples refrigerated or frozen until shipped for testing. Ship frozen samples on dry ice, and refrigerated samples on wet ice

Transportation of Dangerous Goods:

Shipping of specimens shall be done by a TDG certified individual in accordance with TDG regulations. For additional information regarding classification of specimens for the purposes of shipping, consult either Part 2 Appendix 3 of the TDG Regulations or section 3.6.2 of the IATA Dangerous Goods Regulations as applicable.

For additional guidance on the transport of infectious substances in other languages, please click on the link below.

http://www.who.int/ihr/capacity-strengthening/infectious-substances/en/

Patient Criteria:

Suspected Hepatitis B infection.

Accompanying Documentation:

Completed Viral Hepatitis and Bloodborne Pathogens requisition including sender name, address and telephone number.  Patient name or identifier (referring specimen lab #), date of birth, suspected exposure, test(s) requested.  Type of specimen and date collected.  If possible, include the clinical history and lab results that have already been done at local or provincial laboratories.

Comments:

N/A

Methods and Interpretation of Results:

Automated EIA assays. Anti-HBc is used typically as a qualitative serological marker of ongoing or past infection.

Turnaround Time:

15 calendar days.

Contact:
Phone: (204) 789-6061; HCV (204) 789-5063
Fax: (204) 789-2082
References:
  1. Schmidt M, Jimenez A, Mühlbacher A, Oota S, Blanco L, Sakuldamrongpanich T, Schennach H. Seifried E. Head-to_head comparison between two screening systems for HBsAg, anti-HBc, anti-HCV and HIV combination immunoassays in an international, multicentre evaluation study. Vox Sang 2015 109:114-121.
  2. Public Health Agency of Canada (2013) Primary Care Management of Hepatitis B – Quick Reference. Authors: Andonov, A. Ling, R., Baril, J., Myers, R., Brubacher, C., Osiowy, C., Butler, G., Pritchard, L., Gale-Rowe, M., Verkoeyen, J., Heathcote, J., Yim, C., and Latham-Carmanico, C. http://publications.gc.ca/pub?id=439952&sl=0.